High-frequency Launch of Innovative Products, Swisse Nutrition 2025 Net Profit Growth of 19.81% Year-over-Year

On the evening of March 20, Tangchen Beken (300146) released its 2025 annual report. The company continues to deepen its scientific nutrition strategy, using product innovation as a breakthrough, leading to rapid performance stabilization. The report shows that in 2025, Tangchen Beken achieved revenue of 6.265 billion yuan, with net profit attributable to shareholders of listed companies reaching 782 million yuan, a year-on-year increase of 19.81%.

In 2025, the VDS industry continued the trend of declining market size in pharmacy channels, intensified competition in e-commerce channels, and demand segmentation. The increasingly fragmented consumption scenarios have made it difficult for single channels and single categories to meet diverse consumer needs. In response, Tangchen Beken, which adheres to a multi-channel, multi-category, multi-brand layout, continues to launch differentiated new products to cater to different channels and consumer groups.

The newly upgraded Tangchen Beken Blue Can Protein Powder, with a measured protein digestibility of up to 97% and innovative development features such as zero cholesterol, zero lactose, and low fat, meets the high-efficiency supplementation needs of mainstream e-commerce consumers. Since its launch in the second quarter of 2025, it has accumulated sales exceeding 230 million yuan. In April this year, the gold-plated fish oil, launched with the slogan “96% high purity, first-grade freshness,” topped multiple sales rankings on Tmall. Another product, Jingchun Fish Oil, which emphasizes “high EPA+DHA content,” was launched less than a year ago and effectively boosted Tangchen Beken’s market share and repurchase rate in pharmacy channels for fish oil products. The rapid rise of these innovative products demonstrates Tangchen Beken’s agile product development capabilities and comprehensive multi-channel operation strength.

Meanwhile, relying on long-term innovation breakthroughs, Tangchen Beken continues to enhance the technological barriers of its product matrix. During the reporting period, the company launched its first OTC glucosamine sulfate and its first medical food, “Meiyile,” to meet advanced professional needs. The company also continuously improves product nutritional activity and user experience through technological innovation. For example, the multi-dimensional double-layer tablet with “vitamin and mineral layered freshness lock” is a category first, effectively retaining vitamin and mineral activity, which has driven category sales growth; the new launch in May, Lifespace Yibeisi with 96 billion CFU probiotics, added its self-developed patented strain LPB27 to protect gut health and promote autonomous positive gut circulation; in December, BYHEALTH’s high-activity sustained-release B-vitamin complex tablets, which achieve 8-hour release through a sustained-release matrix, immediately topped Tmall International’s new B-vitamin complex vitamin list.

Tangchen Beken’s multi-brand operation demonstrates strong brand incubation capabilities. In 2025, its long-term focus on the infant and child sector, Natural Doctor’s high-end DHA algae oil, ranked first globally in sales*, and launched multiple liquid formulations of minerals and vitamins, expanding from zero to a complete product line and creating a second growth curve. With differentiated, high-end product advantages and a deeply resonant brand image, Natural Doctor’s performance has maintained steady growth in recent years.

2025 marks the first big year for new products in Tangchen Beken’s history. The company focused on new categories, new target groups, and new technologies to strengthen product matrix differentiation, launching over 85 new products throughout the year. This precisely aligned with current VDS consumption trends and achieved remarkable results, with nearly 20% of sales coming from new main brand products in 2025. The “2025 China Dietary Nutritional Supplement Industry Development Report” indicates that consumer decision-making is becoming more rational, with functionality and targeted demographics becoming new variables driving brand growth.

Frequent new product launches are the result of Tangchen Beken’s years of R&D investment. Behind these 85 new products are 30 patents, including 13 invention patents and 4 utility model patents. The rapid rise of many new products also validates Tangchen Beken’s R&D capabilities and technology transfer efficiency. By the end of 2025, the company held 462 domestic patents, including 145 invention patents related to raw materials and formulations, and 18 overseas patents. More patent and scientific research achievements will gradually be applied to products.

Tangchen Beken revealed that in 2026, it will focus on multiple key categories and major innovative products with commercial potential, accelerating the transformation of R&D results into excellent products, strengthening product competitiveness, and launching several high-tech, high-functionality products.

Chairman Liang Yunchao stated that in 2026, Tangchen Beken will adopt a “re-entrepreneurship” mindset, fully engaging, focusing resources on product R&D and innovation, and creating more products that inspire excitement, pride, and emotional connection. The stable performance in 2025 has validated the effectiveness of Tangchen Beken’s strategic approach to breaking through. With the deepening of its scientific nutrition strategy and operational quality improvement measures, the company’s growth potential is expected to be further unleashed.

*Data source: Euromonitor International (Shanghai) Co., Ltd., based on global retail sales of high-end DHA algae oil in 2024, covering 210 countries/regions and various retail channels. High-end DHA algae oil is defined as nutritional products centered on DHA algae oil, including gel candies, softgels, drops, etc., with a unit price above RMB 4 per piece (for non-pellet products, calculated based on the minimum single-use amount of 1 piece). The survey was completed in November 2025.

(Edited by: Guo Jiandong)